Table 1 Characteristics of residents with and without documented exposure to SARS-CoV-2 infected residents

From: Evidence of leaky protection following COVID-19 vaccination and SARS-CoV-2 infection in an incarcerated population

 

Delta predominant period (June 15, 2021–December 12, 2022)

Omicron predominant period (December 13, 2021–May 10, 2022)

Characteristics

Cell exposure events

Cellblock exposure events

Events without documented exposures

Cell exposure events

Cellblock exposure events

Events without documented exposures

(N = 264)

(N = 5616)

(N = 17024)

(N = 702)

(N = 5980)

(N = 13464)

Age (Median [Qr 1-3])

34 [27, 43]

36 [29, 46]

36 [29, 46]

37 [30, 46]

36 [28, 45]

36 [29, 46]

Gender Female (N [%])

38 (14.4%)

383 (6.8%)

1475 (8.7%)

111 (15.8%)

874 (14.6%)

1463 (10.9%)

Race & Ethnicity (N [%])

      

Non-Hispanic Black

126 (47.7%)

2484 (44.2%)

7736 (45.4%)

318 (45.3%)

2644 (44.2%)

6052 (44.9%)

Non-Hispanic White

69 (26.1%)

1482 (26.4%)

4354 (25.6%)

210 (29.9%)

1753 (29.3%)

3987 (29.6%)

Other (Hispanic, American Indian, & Asian)

69 (26.1%)

1650 (29.4%)

4934 (29.0%)

174 (24.8%)

1583 (26.5%)

3425 (25.4%)

Duration of Incarceration (Median [QR 1-3])a

181 [154, 181]

181 [181, 181]

181 [181, 181]

149 [149, 149]

149 [149, 149]

149 [149, 149]

Cell Size (Median [QR 1-3])b

2 [2, 2]

2 [2, 2]

2 [2, 2]

2 [2, 2]

2 [2, 2]

2 [2, 2]

Cellblock Size (Median [QR 1-3])b

74 [56, 129]

107 [69, 155]

88 [65, 140]

82 [61, 104]

89 [67, 133]

89 [65, 120]

History of Prior Infection (N [%])c

85 (32.2%)

2180 (38.8%)

6522 (38.3%)

254 (36.2%)

2606 (43.6%)

6329 (47.0%)

History of Vaccination (N [%])c

109 (41.3%)

3013 (53.7%)

9141 (53.7%)

379 (54.0%)

3401 (56.9%)

7693 (57.1%)

History of Hybrid Immunity (N [%])c

45 (17.0%)

1379 (24.6%)

4289 (25.2%)

168 (23.9%)

1729 (28.9%)

4095 (30.4%)

Follow-up Time (Median [Qr 1-3])

14 [14, 14]

14 [14, 14]

14 [4, 14]

14 [14, 14]

14 [14, 14]

9 [2, 14]

  1. aDuration of incarceration (in days) including the SARS-CoV-2 exposure event type.
  2. bNumber of cellmates or unit-mates at the time of the exposure event that resulted in study inclusion.
  3. cHistory of prior infection defined as a record of prior infection (defined as prior infection defined as the record of a positive SARS-CoV-2 test (rapid antigen or RT-PCR) at least 90 days prior to follow-up start date); history of vaccination defined as receipt of at least one vaccine dose as of the start of follow-up; hybrid immunity defined as a recorded prior infection and vaccination as of the start of the study period.
Back to article page